Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications.
clustered regularly interspaced short palindromic repeats (CRISPR)
functional genomics
gene editing
hematological malignancies
therapeutic targets
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
08
2021
accepted:
17
11
2021
entrez:
14
2
2022
pubmed:
15
2
2022
medline:
15
2
2022
Statut:
epublish
Résumé
Hematological malignancies (HM) are a group of neoplastic diseases that are usually heterogenous in nature due to the complex underlying genetic aberrations in which collaborating mutations enable cells to evade checkpoints that normally safeguard it against DNA damage and other disruptions of healthy cell growth. Research regarding chromosomal structural rearrangements and alterations, gene mutations, and functionality are currently being carried out to understand the genomics of these abnormalities. It is also becoming more evident that cross talk between the functional changes in transcription and proteins gives the characteristics of the disease although specific mutations may induce unique phenotypes. Functional genomics is vital in this aspect as it measures the complete genetic change in cancerous cells and seeks to integrate the dynamic changes in these networks to elucidate various cancer phenotypes. The advent of CRISPR technology has indeed provided a superfluity of benefits to mankind, as this versatile technology enables DNA editing in the genome. The CRISPR-Cas9 system is a precise genome editing tool, and it has revolutionized methodologies in the field of hematology. Currently, there are various CRISPR systems that are used to perform robust site-specific gene editing to study HM. Furthermore, experimental approaches that are based on CRISPR technology have created promising tools for developing effective hematological therapeutics. Therefore, this review will focus on diverse applications of CRISPR-based gene-editing tools in HM and its potential future trajectory. Collectively, this review will demonstrate the key roles of different CRISPR systems that are being used in HM, and the literature will be a representation of a critical step toward further understanding the biology of HM and the development of potential therapeutic approaches.
Identifiants
pubmed: 35154242
doi: 10.3389/fgene.2021.767298
pii: 767298
pmc: PMC8834884
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
767298Informations de copyright
Copyright © 2022 Solayappan, Azlan, Khor, Yik, Khan, Yusoff and Moses.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Natl Compr Canc Netw. 2009 Oct;7(9):908-42
pubmed: 19878637
Blood. 2020 Jul 2;136(1):81-92
pubmed: 32299104
PLoS One. 2014 Jan 20;9(1):e85755
pubmed: 24465685
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Best Pract Res Clin Haematol. 2002 Dec;15(4):597-621
pubmed: 12617866
J Clin Med. 2020 Jun 02;9(6):
pubmed: 32498406
Nature. 2016 May 5;533(7601):125-9
pubmed: 27120160
Oncotarget. 2016 Mar 22;7(12):14350-65
pubmed: 26885608
Hum Mol Genet. 2001 Apr;10(7):769-75
pubmed: 11257111
Blood Lymphat Cancer. 2019 Nov 27;9:53-61
pubmed: 31819702
Nat Methods. 2014 Apr;11(4):429-35
pubmed: 24531420
Sci Rep. 2021 Jun 23;11(1):13158
pubmed: 34162911
Haematologica. 2020 Jul 03;105(9):2205-2217
pubmed: 33054046
Nature. 2016 Jan 28;529(7587):490-5
pubmed: 26735016
Leukemia. 2017 Sep;31(9):1882-1893
pubmed: 28017968
Mol Cancer Ther. 2017 Dec;16(12):2862-2870
pubmed: 28958990
Cancer Cell. 2019 Mar 18;35(3):369-384.e7
pubmed: 30799057
Trends Cancer. 2018 Jul;4(7):499-512
pubmed: 29937048
BMC Bioinformatics. 2013 Jan 23;14:29
pubmed: 23343428
Cell Death Dis. 2021 Apr 28;12(5):419
pubmed: 33911074
Blood. 2018 Jun 14;131(24):2617-2620
pubmed: 29728405
PLoS One. 2016 Apr 15;11(4):e0153689
pubmed: 27081855
Clin Cancer Res. 2020 Jan 1;26(1):256-264
pubmed: 31573954
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Int J Clin Exp Pathol. 2015 Oct 01;8(10):13707-10
pubmed: 26722598
Trends Microbiol. 2017 Jan;25(1):49-61
pubmed: 27773522
J Med Genet. 2019 Jan;56(1):4-9
pubmed: 29970486
Nature. 2018 Aug;560(7718):387-391
pubmed: 29925955
Clin Transl Med. 2021 Feb;11(2):e304
pubmed: 33634999
Leukemia. 2021 Apr;35(4):1012-1022
pubmed: 32764680
Blood. 2015 Aug 13;126(7):833-41
pubmed: 25966987
Methods. 2017 May 15;121-122:1-2
pubmed: 28645537
Nat Methods. 2013 Mar;10(3):243-5
pubmed: 23396285
Cancer Biol Ther. 2018 Aug 3;19(8):676-686
pubmed: 29565710
PLoS One. 2021 Jan 8;16(1):e0245349
pubmed: 33418558
Blood Adv. 2020 Jul 14;4(13):2899-2911
pubmed: 32589729
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Leukemia. 2020 Jun;34(6):1599-1612
pubmed: 31974435
Nat Rev Dis Primers. 2017 Jan 19;3:16096
pubmed: 28102226
Blood. 2017 Jun 15;129(24):3221-3226
pubmed: 28270453
Curr Opin Microbiol. 2017 Jun;37:67-78
pubmed: 28605718
Cancers (Basel). 2020 May 29;12(6):
pubmed: 32485885
Ann Hematol. 2010 Mar;89(3):241-7
pubmed: 19714331
Blood. 2018 Jan 18;131(3):311-322
pubmed: 29122757
Blood. 2016 May 26;127(21):2587-97
pubmed: 26907633
Nat Biotechnol. 2013 Sep;31(9):827-32
pubmed: 23873081
Blood Adv. 2019 Jul 23;3(14):2105-2117
pubmed: 31300418
Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):710-723
pubmed: 30093283
Leukemia. 2011 Dec;25(12):1869-1876
pubmed: 21701491
Cell Rep. 2016 Oct 18;17(4):1193-1205
pubmed: 27760321
Cancer Discov. 2022 Feb;12(2):432-449
pubmed: 34531254
Genome Res. 2014 Jun;24(6):1012-9
pubmed: 24696461
Sci Rep. 2016 Dec 16;6:38968
pubmed: 27982060
Front Microbiol. 2020 Jan 22;10:3078
pubmed: 32038537
Cancer Discov. 2016 Aug;6(8):914-29
pubmed: 27260156
Nat Cancer. 2020 Apr;1(4):410-422
pubmed: 34109316
Science. 2018 Sep 21;361(6408):1259-1262
pubmed: 30166441
Nat Biotechnol. 2009 Sep;27(9):851-7
pubmed: 19680244
Cells. 2020 Jan 15;9(1):
pubmed: 31952221
Int J Mol Sci. 2019 May 08;20(9):
pubmed: 31071955
Nat Rev Genet. 2016 May;17(5):300-12
pubmed: 27087594
Nature. 2007 Apr 12;446(7137):758-64
pubmed: 17344859
ISRN Oncol. 2014 Jan 30;2014:596483
pubmed: 24634785
Nat Protoc. 2021 Feb;16(2):1170-1192
pubmed: 33462439
Yale J Biol Med. 2012 Jun;85(2):187-200
pubmed: 22737048
Cell Mol Life Sci. 2007 Nov;64(22):2933-44
pubmed: 17763826
Cell Death Dis. 2017 Jan 12;8(1):e2547
pubmed: 28079885
Blood. 2017 Jul 27;130(4):410-423
pubmed: 28600336
Leuk Lymphoma. 2020 Dec;61(13):3078-3088
pubmed: 32815753
Sci Adv. 2021 May 19;7(21):
pubmed: 34138728
Nat Biotechnol. 2018 Jul;36(6):512-520
pubmed: 29734294
Blood. 2002 Sep 1;100(5):1628-33
pubmed: 12176881
Curr Res Transl Med. 2018 May;66(2):39-42
pubmed: 29691200
Haematologica. 2020 May;105(5):e232-e236
pubmed: 31537693
Curr Gene Ther. 2017;17(4):263-274
pubmed: 29173169
Front Oncol. 2020 Apr 03;10:448
pubmed: 32309216
Nucleic Acids Res. 2014 Jun;42(11):7473-85
pubmed: 24838573
Nature. 2017 Oct 12;550(7675):280-284
pubmed: 28976959
Cancer Commun (Lond). 2020 Oct;40(10):501-517
pubmed: 32820611
Blood. 2021 Apr 22;137(16):2171-2181
pubmed: 33270841
Mol Ther Nucleic Acids. 2019 Mar 1;14:212-238
pubmed: 30641475
Mol Cell. 2016 Aug 4;63(3):355-70
pubmed: 27494557
Cancer Res. 2005 Oct 1;65(19):8912-9
pubmed: 16204063
Mol Pharmacol. 2021 Mar;99(3):226-241
pubmed: 33446509
Nat Biotechnol. 2016 May;34(5):528-30
pubmed: 27088723
Cell. 2017 Oct 5;171(2):481-494.e15
pubmed: 28985567
Transgenic Res. 2021 Apr;30(2):129-141
pubmed: 33609253
Science. 2017 Nov 24;358(6366):1019-1027
pubmed: 29070703
Haematologica. 2020 Apr;105(4):925-936
pubmed: 31467124
Exp Hematol. 2017 Oct;54:1-3
pubmed: 28668351
Cell Stem Cell. 2021 Apr 1;28(4):718-731.e6
pubmed: 33450187
Blood. 2019 Feb 21;133(8):830-839
pubmed: 30510140
Drug Deliv. 2018 Nov;25(1):1234-1257
pubmed: 29801422
Cells. 2020 Jul 02;9(7):
pubmed: 32630835
Mol Microbiol. 2013 Mar;87(5):1088-99
pubmed: 23320564
J Mol Biol. 2019 Jan 4;431(1):48-65
pubmed: 29959923
Oncologist. 2004;9(3):271-81
pubmed: 15169982
Leukemia. 2015 Oct;29(10):2015-23
pubmed: 25971364
Cell. 2015 Dec 3;163(6):1515-26
pubmed: 26627737
Signal Transduct Target Ther. 2020 Jan 3;5(1):1
pubmed: 32296011
Nat Cancer. 2020 Mar;1(3):359-369
pubmed: 33345196
Blood Cancer J. 2017 Jun 30;7(6):e577
pubmed: 28665419
Nucleic Acids Res. 2014 Feb;42(3):1563-74
pubmed: 24194590
Science. 2016 Jan 1;351(6268):84-8
pubmed: 26628643
Cell Stem Cell. 2021 Jun 3;28(6):1074-1089.e7
pubmed: 33571445
Lancet. 2013 Jun 1;381(9881):1943-55
pubmed: 23523389
Science. 2014 Jan 3;343(6166):80-4
pubmed: 24336569
Cell. 2014 Jun 5;157(6):1262-1278
pubmed: 24906146
Cell Rep. 2016 Feb 16;14(6):1555-1566
pubmed: 26854237
Blood Cancer J. 2021 Jul 9;11(7):127
pubmed: 34244476
Cancer Discov. 2016 Aug;6(8):900-13
pubmed: 27260157
Blood Adv. 2021 May 11;5(9):2391-2402
pubmed: 33950175
Cancer Cell. 2018 Mar 12;33(3):386-400.e5
pubmed: 29478914
Leukemia. 2021 Apr;35(4):1087-1099
pubmed: 32782381
Cytogenet Genome Res. 2015;147(1):1-9
pubmed: 26583376
Mol Ther Nucleic Acids. 2017 Mar 17;6:243-248
pubmed: 28325290
Nature. 2017 Feb 23;542(7642):479-483
pubmed: 28192788
Blood. 2019 Nov 7;134(19):1598-1607
pubmed: 31558468
Clin Cancer Res. 2017 May 1;23(9):2255-2266
pubmed: 27815355
Nat Commun. 2018 Sep 21;9(1):3839
pubmed: 30242258
Cancer Discov. 2020 Jul;10(7):998-1017
pubmed: 32349972
Nat Commun. 2018 May 22;9(1):2024
pubmed: 29789628
J Clin Invest. 2014 Oct;124(10):4154-61
pubmed: 25271723
Leukemia. 2021 May;35(5):1229-1242
pubmed: 33833387
Cancer Discov. 2016 Aug;6(8):824-6
pubmed: 27485003
Materials (Basel). 2021 Jun 09;14(12):
pubmed: 34207502
Cancer Cell. 2018 Dec 10;34(6):982-995.e7
pubmed: 30503705
Cell Host Microbe. 2017 Sep 13;22(3):343-353.e3
pubmed: 28826839
Biomater Sci. 2018 May 29;6(6):1592-1603
pubmed: 29725684
Blood Cancer Discov. 2021 Sep;2(5):518-531
pubmed: 34568834
Biol Proced Online. 2020 Nov 7;22(1):24
pubmed: 33292172
Oncotarget. 2015 Dec 29;6(42):44061-71
pubmed: 26623729
Blood. 2019 Jul 11;134(2):171-185
pubmed: 31151983
Curr Protoc Mol Biol. 2019 Jun;127(1):e89
pubmed: 31237422
J Cell Biochem. 2017 Dec;118(12):4152-4162
pubmed: 28467679
Zhonghua Xue Ye Xue Za Zhi. 2021 Mar 14;42(3):243-249
pubmed: 33910311
Front Mol Biosci. 2020 Feb 21;7:24
pubmed: 32154266
Curr Oncol Rep. 2020 Mar 14;22(4):36
pubmed: 32172299
Nat Biotechnol. 2019 Jun;37(6):657-666
pubmed: 30988504